These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9164209)

  • 1. Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.
    O'Reilly S; Grochow LB; Donehower RC; Chen TL; Bowling K; Hartman NR; Struck RF; Rowinsky EK
    J Clin Oncol; 1997 May; 15(5):1974-84. PubMed ID: 9164209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.
    Liu G; Berlin J; Tutsch KD; Van Ummersen L; Dresen A; Marnocha R; Arzomanian R; Alberti D; Feierabend C; Binger K; Wilding G
    Clin Cancer Res; 2002 Mar; 8(3):706-11. PubMed ID: 11895899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy.
    Berlin J; Stewart JA; Storer B; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Wilding G
    J Clin Oncol; 1998 Mar; 16(3):1142-9. PubMed ID: 9508201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
    Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.
    Jodrell DI; Bowman A; Stewart M; Dunlop N; French R; MacLellan A; Cummings J; Smyth JF
    Br J Cancer; 1998 Mar; 77(5):808-11. PubMed ID: 9514062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
    Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
    J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
    Briasoulis E; Judson I; Pavlidis N; Beale P; Wanders J; Groot Y; Veerman G; Schuessler M; Niebch G; Siamopoulos K; Tzamakou E; Rammou D; Wolf L; Walker R; Hanauske A
    J Clin Oncol; 2000 Oct; 18(20):3535-44. PubMed ID: 11032596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine.
    O'Reilly S; Hartman NR; Bowling KM; Rowinsky EK; Donehower RC; Collins J; Strong JM
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):223-8. PubMed ID: 11592344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
    Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
    Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
    Villalona-Calero MA; Eckhardt SG; Weiss G; Hidalgo M; Beijnen JH; van Kesteren C; Rosing H; Campbell E; Kraynak M; Lopez-Lazaro L; Guzman C; Von Hoff DD; Jimeno J; Rowinsky EK
    Clin Cancer Res; 2002 Jan; 8(1):75-85. PubMed ID: 11801542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
    Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
    Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
    Tolcher AW; Aylesworth C; Rizzo J; Izbicka E; Campbell E; Kuhn J; Weiss G; Von Hoff DD; Rowinsky EK
    Ann Oncol; 2000 Mar; 11(3):333-8. PubMed ID: 10811501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
    Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
    Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum.
    O'Reilly S; O'Hearn E; Struck RF; Rowinsky EK; Molliver ME
    Invest New Drugs; 2003 Aug; 21(3):269-79. PubMed ID: 14578677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.